Raymond James Financial Services Advisors Inc. Raises Holdings in Flexion Therapeutics Inc (NASDAQ:FLXN)

Raymond James Financial Services Advisors Inc. increased its stake in shares of Flexion Therapeutics Inc (NASDAQ:FLXN) by 6.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 72,595 shares of the specialty pharmaceutical company’s stock after acquiring an additional 4,356 shares during the period. Raymond James Financial Services Advisors Inc. owned about 0.19% of Flexion Therapeutics worth $822,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Rubric Capital Management LP increased its stake in Flexion Therapeutics by 7.7% in the 3rd quarter. Rubric Capital Management LP now owns 2,125,000 shares of the specialty pharmaceutical company’s stock valued at $39,759,000 after buying an additional 151,286 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Flexion Therapeutics by 6.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 152,355 shares of the specialty pharmaceutical company’s stock valued at $2,851,000 after acquiring an additional 9,460 shares during the period. Vanguard Group Inc grew its position in shares of Flexion Therapeutics by 1.1% in the 3rd quarter. Vanguard Group Inc now owns 1,619,112 shares of the specialty pharmaceutical company’s stock valued at $30,294,000 after acquiring an additional 18,323 shares during the period. Capital International Investors bought a new position in shares of Flexion Therapeutics in the 3rd quarter valued at about $12,162,000. Finally, Virtu Financial LLC bought a new position in shares of Flexion Therapeutics in the 4th quarter valued at about $240,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

A number of research analysts have recently commented on the stock. BidaskClub downgraded shares of Flexion Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Zacks Investment Research downgraded shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 8th. Wells Fargo & Co reissued a “buy” rating on shares of Flexion Therapeutics in a research report on Wednesday, April 10th. Raymond James reissued a “buy” rating on shares of Flexion Therapeutics in a research report on Thursday, March 28th. Finally, ValuEngine downgraded shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $22.64.

Shares of NASDAQ:FLXN traded up $0.12 during midday trading on Monday, hitting $10.63. The stock had a trading volume of 530,000 shares, compared to its average volume of 684,817. The stock has a market capitalization of $395.86 million, a PE ratio of -2.37 and a beta of 1.68. The company has a current ratio of 7.78, a quick ratio of 7.58 and a debt-to-equity ratio of 1.35. Flexion Therapeutics Inc has a fifty-two week low of $9.90 and a fifty-two week high of $29.10.

In other news, insider Michael D. Clayman bought 4,046 shares of the company’s stock in a transaction dated Tuesday, March 12th. The stock was bought at an average cost of $12.36 per share, for a total transaction of $50,008.56. Following the transaction, the insider now owns 70,856 shares of the company’s stock, valued at $875,780.16. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 14.59% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: “Raymond James Financial Services Advisors Inc. Raises Holdings in Flexion Therapeutics Inc (NASDAQ:FLXN)” was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.baseballdailydigest.com/news/2019/04/15/raymond-james-financial-services-advisors-inc-has-822000-position-in-flexion-therapeutics-inc-flxn.html.

Flexion Therapeutics Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Featured Article: Do closed-end mutual funds pay dividends?

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.